- Corporate restructuring and associated headcount reduction may not result in anticipated savings, could result in higher than expected costs, and could disrupt business.
- Drug development is expensive, time-consuming, and uncertain; regulatory approvals are not guaranteed.
- Limited experience in conducting and managing clinical studies necessary to obtain regulatory approval.
- Potential impacts of war, terrorism, geopolitical uncertainties, and business interruptions could disrupt operations and supply chains.
- Significant losses incurred since inception and anticipation of continued losses for the foreseeable future; need for substantial additional funding.
- Compliance with Nasdaq’s continued listing requirements.
Affimed N.V.
Greenhouse gas emissions & sustainability report data
Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2022 | 1.2K tCO2e/year (estimate) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Implemented EHS Management System including objective setting, risk assessment, preventive measures, training, and reporting; committed to sensitive travel, reduced electricity use, and promoting working from home to reduce carbon footprint; continuously reducing CO2 emissions and energy consumption, avoiding waste, and increasing use of renewable, recycled, and recyclable materials.
- Issued first sustainability report in 2023.
🌱 ESG Focus Areas
Environmental, Social, and Governance (ESG)